177Lu-DOTA-EB-TATE
- Generic Name
- 177Lu-DOTA-EB-TATE
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
Phase 1
Recruiting
- Conditions
- Neuroendocrine Tumors
- Interventions
- Other: Amino Acid Solution
- First Posted Date
- 2022-07-26
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Molecular Targeting Technologies, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05475210
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03308682
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath